AI in Healthcare

Today's Stories

1. 1

   RIZAP employee leaks 210 IHI health-insurance records to AI, OpenAI notified

   RIZAP Group said an employee mistakenly uploaded personal data, including names and disease details of 210 people covered by IHI's health insurance, to a generative AI for personal use. This marks a shift from internal data-handling policies to a real incident involving health information, which is highly sensitive. RIZAP publicly disclosed the breach to OpenAI, signaling a new level of accountability.

   How RIZAP and IHI respond to affected individuals and regulators. The number of affected people (210) is a concrete figure to monitor for any updates.

2. 2

   CRIO panel: build data infrastructure before AI tools

   A panel convened by CRIO and Clinical Leader advised sites to move to electronic systems, establish AI governance, and give staff enterprise LLM accounts before custom AI tools. Three-quarters of sites now use eSource, but the panel said the buy-or-build question is premature for most, as skipping the foundation creates cleanup work rather than eliminating it.

   Whether a site can show exactly which data fed an AI model and which human reviewed the result, a marker of readiness under ICH E6(R3)'s documentation burden.

3. 3

   Kakehashi CEO: AI era brings 'oshi no yakuzaishi'

   Kakehashi CEO Nakagawa said the AI era is when 'oshi no yakuzaishi' (a pharmacist you root for) becomes key, as electronic prescriptions and generative AI change pharmacy work. Pharmacies used to handle everything in-store from prescription to counseling; now the model is shifting toward digital tools and AI, making the pharmacist's personal touch a differentiator.

   Watch whether Kakehashi's cloud services for dispensing pharmacies help realize this vision, as the article says the shift is 'beginning to change' rather than fully underway.

4. 4

   Google DeepMind unveils AlphaGenome Atlas to map genome variants

   Google DeepMind unveiled AlphaGenome Atlas, a platform with a predictive map of every possible DNA letter change, covering nine billion variants. It launched today for noncommercial researcher use. Atlas extends beyond AlphaMissense, which focused on protein-altering mutations, to cover genome stretches that control gene behavior. This offers a more complete catalog of how mutations affect molecular biology.

   The test is whether the Atlas's predictions accelerate disease research and treatment discovery. Access for commercial use is coming "soon" on Google Cloud, which could broaden its impact.

5. 5

   AI Lung Drug Lowers Biological Age in Trial

   In a midstage study, Insilico Medicine’s drug rentosertib reduced biological age, measured by six aging clocks, per an analysis in Nature Biotechnology. Placebo recipients saw little change. The result suggests an AI-discovered lung drug may reverse aging markers, not just treat disease, a new potential use. The company is Hong Kong-listed.

   Whether the early results hold in larger, longer studies; the analysis included only 42 patients with chronic lung disease. CEO Alex Zhavoronkov cautioned the long-term health effects are unknown.

6. 6

   Insilico's rentosertib shows early aging signal in IPF trial

   Insilico Medicine published an exploratory analysis in Nature Biotechnology showing rentosertib shifted blood markers toward younger age estimates in 42 IPF patients. At week four, patients on 60 mg once daily showed estimated age reductions of 2.71 to 3.46 years across four clocks, but the analysis cannot prove the drug slows aging.

   The findings hinge on whether larger studies show durable lung-function benefit and acceptable safety; 16 participants discontinued treatment, with liver toxicity and diarrhea among the leading reasons.